From breakthrough to cure: What will define the next era of oncology?

​Teaser
Cancer treatment is entering a new phase, not through a single breakthrough, but through the convergence of multiple high-impact technologies.
Next-generation immunotherapies are becoming smarter, more durable, and increasingly “off-the-shelf,” expanding their reach beyond blood cancers into solid tumors. At the same time, radiotherapy is evolving into a highly precise, adaptive tool , from IMRT to stereotactic approaches, and is now being combined with immunotherapy and personalized medicine strategies.
Alongside this, new modalities such as proton therapy, Tumor Treating Fields, and targeted protein degradation are opening up entirely new ways to attack cancer, including targets that were previously considered undruggable.
The result: a shift from isolated treatments to integrated, multi-modal strategies that aim to improve efficacy, reduce toxicity, and fundamentally change how cancer is treated.

​Why is this topic relevant?
The question is highly relevant because oncology is currently undergoing a profound transformation driven by several breakthrough technologies at once. As the teaser suggests, cancer treatment is no longer developing along separate tracks, but through the convergence of next-generation immunotherapies, advanced radiotherapy techniques, and novel therapeutic platforms such as proton therapy, Tumor Treating Fields, and protein-degrading drugs. Together, these innovations are reshaping what is possible in cancer care: they aim not only to improve precision and efficacy, but also to reduce toxicity, overcome resistance, and expand treatment options for patients with difficult-to-treat cancers, including solid tumors. This makes the question especially timely, since understanding how these approaches interact, complement one another, and move toward more personalized and durable care is central to the future of modern oncology.

​The session will take place on the VITALA Planet at VENTURE SPRIND 2026, held at Futurium in Berlin. You will need a VENTURE SPRIND ticket to enter the venue and attend the session.
If you don’t have one yet but are an active investor, just drop us a line at [email protected] - there’s a good chance we can sort you out with a ticket. Availability is limited.